(Reuters) - Full data from a late-stage clinical trial of Biogen Idec Inc's experimental multiple sclerosis drug, BG-12, showed robust results across multiple measures and revealed no new safety concerns. The news sent the biotech company's shares ... Biogen MS trial data robust; shares jump
Thursday, October 20, 2011
Biogen MS trial data robust; shares jump
(Reuters) - Full data from a late-stage clinical trial of Biogen Idec Inc's experimental multiple sclerosis drug, BG-12, showed robust results across multiple measures and revealed no new safety concerns. The news sent the biotech company's shares ... Biogen MS trial data robust; shares jump
Subscribe to:
Post Comments (Atom)
Popular Posts
-
Miami (EEEU), 7 oct (EFE).- El cubano René González, que pasó 13 años en prisión en EE.UU. por espionaje, salió hoy de la cárcel, pero no p...
-
Russians have spoken, and more loudly than expected. The fall of nearly a quarter in the ruling United Russia party's share of Sunday...
No comments:
Post a Comment